Drug Trial Radar · NCT02205762
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,400
Actual
Start
Nov 2, 2016
Primary completion
Nov 2031
Study completion Nov 2031
Sponsor
- Lead sponsor
- North American Consortium for HistiocytosisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Histiocyte Society
- First posted
- Jul 31, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Conditions
- Langerhans Cell Histiocytosis
Interventions
PrednisoneDrug
Stratum I
VinblastineDrug
Stratum I
mercaptopurineDrug
Stratum I
INDOMETHACINDrug
Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
MethotrexateDrug
fixed dose weekly orally for total treatment duration of 24 months.
Cytosine ArabinosideDrug
2-chlorodeoxyadenosineDrug
hematopoietic stem cell transplantation (RIC-HSCT)Procedure
Intravenous immunoglobulinBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients with Reactivation Free SurvivalTime frame: 12 Months
- Response Rate of Second CycleTime frame: 9 weeks
- Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)Time frame: 3 Years
- The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesionsTime frame: 2 Years
- The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCHTime frame: 2 Years
- Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.Time frame: 2 Years
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Children's of Alabama
Birmingham, Alabama
Phoenix Children's Hospital
Phoenix, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Children's Hospital of Los Angeles
Los Angeles, California
Valley Children's Healthcare
Madera, California
UCSF Benioff Children's Hospital of Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
UCSF Helen Diller Family Cancer Center
San Francisco, California
Connecticut Children's Medical Center
Hartford, Connecticut
Children's National Medical Center
Washington D.C., District of Columbia
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Children's Healthcare of Atlanta, Emory
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Riley Hospital for Children - Indiana University
Indianapolis, Indiana
Children's Mercy Hospitals
Kansas City, Kansas
University of Kentucky A.B.Chandler Medical Center
Lexington, Kentucky
University of Louisville, Norton Children's Hospital
Louisville, Kentucky
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Children's Minnesota
Minneapolis, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Cohen Children's Medical Center
New Hyde Park, New York
Mount Sinai Hospital
New York, New York
Columbia University / Herbert Irving Cancer Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Children's Hospital at Montefiore
The Bronx, New York
Carolinas Medical Center, Levine Children's Hospital
Charlotte, North Carolina
Akron Children's Hospital
Akron, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Rainbow Babies & Children's Hospital, University Hospitals
Cleveland, Ohio
Russell J Ebeid Children's Hospital (Promedica)
Toledo, Ohio
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Greenville Health System BI-LO Charities Children's Cancer Center
Greenville, South Carolina
St. Jude Children's Research Hospital
Memphis, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Children's Medical Center Dallas, UT Southwestern
Dallas, Texas
Providence Sacred Heart Children's Hospital
Spokane, Washington
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.